AMRX Amneal Pharmaceuticals (AMRX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001723128
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
188
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $3.2M priced
What the filings say about AMRX
Insiders, 180 days
-$7.7M net sold
4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$10.0M
4 notices
Amneal Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Amneal Pharmaceuticals, Inc. insiders sold a net $7.7M of stock across 54 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 27, 2025.
- The trade is 23.8% of the 210,252 shares held after it.
- 2 other insiders sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kiely John sold about $882.0K of AMRX on Aug 13, 2026; 2 other insiders sold within 30 days and 188 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Nov 12, 2025.
- The trade is 57.8% of the 253,390 shares held after it.
- 2 other insiders sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice President Shah Nikita sold about $2.6M of AMRX on Aug 12, 2026; 2 other insiders sold within 30 days and 188 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 11, 2026.
- The trade is 597.1% of the 35,171 shares held after it.
- 2 other insiders sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Legal Officer Daly Jason B. sold about $3.7M of AMRX on Aug 12, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 188 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 12, 2025.
- The trade is 2.7% of the 245,171 shares held after it.
- 2 other insiders sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Legal Officer Daly Jason B. sold about $117.1K of AMRX on Aug 11, 2026; 2 other insiders sold within 30 days and 188 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Nov 22, 2024.
- The trade is 37.2% of the 93,660 shares held after it.
- No other insider sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Autor Deborah M. sold about $450.6K of AMRX on May 11, 2026; 188 funds added in the latest 13F quarter.54 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$7.7M over 180 days
-$7.2M over 90 days
below 82% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
188 funds bought in last quarter
more than 88% of Pharma & Biotech
Revenue
+8.0% year over year
more than 57% of Pharma & Biotech
Margin
2.4% net margin
more than 75% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.1% of the float short (float per yahoo 2026-10-27) · 3.7 days to cover · settled 2026-10-15
below 51% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AMRX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+105.8%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AMRX: institutional holders (13F)
13F holdings, latest reported quarter
26,562,093 sh
$459.8M
12,328,767 sh
$213.4M
12,137,727 sh
$210.1M
10,168,660 sh
$176.0M
7,710,126 sh
$133.5M
Congress trades in AMRX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AMRX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JOHN KIELY
Filed 2026-08-13
$879.7K
JASON DALY
Filed 2026-08-12
$3.6M
NIKITA SHAH
Filed 2026-08-12
$2.6M
BUCHI J KEVIN
Filed 2026-08-11
$2.9M
AMRX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Pharmaceuticals ETF
$17.7M position · as of 2026-07-31
3.7%
Allspring SMID Core ETF
$2.9M position · as of 2026-06-30
2.4%
VY Columbia Small Cap Value and Inflection Portfolio
$1.4M position · as of 2026-06-30
1.8%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$7.4M position · as of 2026-06-30
1.7%
AltShares Event-Driven ETF
$210.7K position · as of 2026-05-31
1.7%
Water Island Event-Driven Fund
$842.9K position · as of 2026-05-31
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
1
Phase 3
1 active
What changed recently
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequi
2026-09-03 · Recruiting → Unknown
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Amneal Pharmaceuticals Inc. Pac
Cycle 2026 · $30K spent
$53.7K
Federal Election Commission, matched by the PAC's connected organisation
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $7.7M sold by insiders over 180 days, 188 funds added last quarter, $10.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
AMRX financials
Revenue growth
+8.0%
XBRL, annual
Net margin
2.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AMRX
| FY Dec 2025 | $3.0B |
| FY Dec 2024 | $2.8B |
| FY Dec 2023 | $2.4B |
| FY Dec 2022 | $2.2B |
| FY Dec 2021 | $2.1B |
| Jun 2026 | $796.2M |
| Mar 2026 | $722.5M |
| Dec 2025 | $814.3M |
| Sep 2025 | $784.5M |
| Jun 2025 | $724.5M |
| Mar 2025 | $695.4M |
| Dec 2024 | $730.5M |
| Sep 2024 | $702.5M |
At each fiscal year end
Single quarter
Net margin, TTM
+5.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AMRX
| FY Dec 2025 | +2.4% |
| FY Dec 2024 | -4.2% |
| FY Dec 2023 | -3.5% |
| FY Dec 2022 | -12.2% |
| FY Dec 2021 | +0.6% |
| Jun 2026 | +7.2% |
| Mar 2026 | +8.6% |
| Dec 2025 | +4.3% |
| Sep 2025 | +0.3% |
| Jun 2025 | +3.1% |
| Mar 2025 | +1.8% |
| Dec 2024 | -4.3% |
| Sep 2024 | -0.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$127.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AMRX
| FY Dec 2025 | $269.9M |
| FY Dec 2024 | $243.2M |
| FY Dec 2023 | $302.4M |
| FY Dec 2022 | $18.7M |
| FY Dec 2021 | $194.1M |
| Jun 2026 | -$51.9M |
| Mar 2026 | -$34.9M |
| Dec 2025 | $108.5M |
| Sep 2025 | $106.2M |
| Jun 2025 | $61.0M |
| Mar 2025 | -$5.8M |
| Dec 2024 | $102.9M |
| Sep 2024 | $124.8M |
At each fiscal year end
Single quarter
Debt to equity
77.83x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity AMRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 122.35x |
| FY Dec 2022 | 8.79x |
| FY Dec 2021 | 7.52x |
| Jun 2026 | 77.83x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.08x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt AMRX
| FY Dec 2025 | 0.13x |
| FY Dec 2024 | 0.12x |
| FY Dec 2023 | 0.14x |
| FY Dec 2022 | 0.02x |
| FY Dec 2021 | 0.09x |
| Jun 2026 | 0.08x |
| Mar 2026 | 0.12x |
| Dec 2025 | 0.13x |
| Sep 2025 | 0.13x |
| Jun 2025 | 0.16x |
| Mar 2025 | 0.14x |
| Dec 2024 | 0.12x |
| Sep 2024 | 0.13x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity AMRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -52.8% |
| FY Dec 2022 | -82.1% |
| FY Dec 2021 | +4.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -155.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AMRX
| FY Dec 2025 | +2.0% |
| FY Dec 2024 | -3.4% |
| FY Dec 2023 | -2.3% |
| FY Dec 2022 | -7.0% |
| FY Dec 2021 | +0.3% |
| Jun 2026 | +4.4% |
| Mar 2026 | +3.5% |
| Dec 2025 | +2.0% |
| Sep 2025 | +0.2% |
| Jun 2025 | +0.1% |
| Mar 2025 | -0.4% |
| Dec 2024 | -3.4% |
| Sep 2024 | -5.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -7%, not meaningful
Return on invested capital AMRX
| FY Dec 2025 | +15.8% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +3.6% |
| Jun 2026 | n/a |
| Mar 2026 | +18.4% |
| Dec 2025 | +15.8% |
| Sep 2025 | +12.9% |
| Jun 2025 | +10.6% |
| Mar 2025 | +9.9% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+17.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AMRX
| FY Dec 2025 | +15.3% |
| FY Dec 2024 | +10.0% |
| FY Dec 2023 | +7.2% |
| FY Dec 2022 | -3.0% |
| FY Dec 2021 | +4.6% |
| Jun 2026 | +17.4% |
| Mar 2026 | +17.1% |
| Dec 2025 | +15.3% |
| Sep 2025 | +14.0% |
| Jun 2025 | +16.0% |
| Mar 2025 | +14.7% |
| Dec 2024 | +10.0% |
| Sep 2024 | +7.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
43.76x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing AMRX
| FY Dec 2025 | 54.78x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 68.43x |
| Jun 2026 | 35.33x |
| Mar 2026 | 32.71x |
| Dec 2025 | 54.78x |
| Sep 2025 | 500.50x |
| Jun 2025 | 809.00x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$9.3B
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value AMRX
| FY Dec 2025 | $6.3B |
| FY Dec 2024 | $4.7B |
| FY Dec 2023 | $2.3B |
| FY Dec 2022 | $2.6B |
| FY Dec 2021 | $2.5B |
| Jun 2026 | $8.0B |
| Mar 2026 | $6.3B |
| Dec 2025 | $6.3B |
| Sep 2025 | $5.5B |
| Jun 2025 | $4.6B |
| Mar 2025 | $4.7B |
| Dec 2024 | $4.7B |
| Sep 2024 | $4.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield AMRX
| FY Dec 2025 | +6.8% |
| FY Dec 2024 | +9.9% |
| FY Dec 2023 | +4,981,235% |
| FY Dec 2022 | +939,347% |
| FY Dec 2021 | +4,052,025% |
| Jun 2026 | +2.3% |
| Mar 2026 | +6.2% |
| Dec 2025 | +6.8% |
| Sep 2025 | +8.4% |
| Jun 2025 | +11.2% |
| Mar 2025 | +9.7% |
| Dec 2024 | +9.9% |
| Sep 2024 | +10.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.01x
P/E over trailing EPS growth of 4800%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing AMRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.01x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.0B | $2.8B | $2.4B | $2.2B |
| Gross profit | $1.1B | $1.0B | $820.6M | $784.7M |
| Operating income | $394.1M | $249.3M | $204.4M | -$94.9M |
| Net income | $72.1M | -$116.9M | -$84.0M | -$270.6M |
| EPS (diluted) | 0.22 | -0.38 | -0.48 | -0.86 |
| Operating cash flow | $340.0M | $295.1M | $345.6M | $65.1M |
| Cash | $282.0M | $110.6M | $91.5M | $26.0M |
| Long-term debt | $2.6B | $2.2B | $2.4B | $2.6B |
SEC XBRL, fiscal years, as known on 2026-10-28
AMRX Stock Sonar score 6/7 axes
Find similar shapesCompareAMRX ranks highest on profitability (89th percentile) and institutional and government (82nd), and lowest on insider conviction (8th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AMRX filings, in plain words
Are Amneal Pharmaceuticals insiders buying or selling AMRX?
In the 180 days to 2026-10-28, Amneal Pharmaceuticals insiders were net sellers, a net $7.7M across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of AMRX?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $10.0M of stock; the latest, by JOHN KIELY, was filed 2026-08-13.
Read the full summary
In the 180 days to 2026-10-28, Amneal Pharmaceuticals insiders were net sellers of AMRX, a net $7.7M across purchases and sales reported on Form 4 by 4 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $10.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
